**Technology:**  Indication for use of niacin (nicotinic acid) for treatment and reversal of fatty liver disease

**VA ID Number**  2014-0092

**Inventor:**  Moti Kashyap

**Location:**  Long Beach, CA

**Topic:**  Diagnostics

**USPTO Issue Date:**  7/07/2015

**Patent Number:**  9,072,732

The VA has a joint ownership interest with The Regents of the University of California

**Contact:**  lee.sylvers@va.gov

**Abstract:**  Niacin prevents and/or reverses the development of experimental hepatic steatosis, deposition of triglycerides in liver and serum of individuals, deposition of total cholesterol in liver and serum in individuals, and inhibit liver lipid peroxidation and oxidative stress in individuals at risk of developing fatty liver disease or NAFLD. In cultured human hepatocytes, niacin inhibits alcohol-induced fat accumulation.